Phase 2 study provides proof of concept for TDV and supports the ongoing phase 3 efficacy assessment

DENV serotype-specific antibody titres persist even after 18 months of vaccination, finds study.
DENV serotype-specific antibody titres persist even after 18 months of vaccination, finds study.